Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2001-12-12
2003-05-06
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S468000, C424S469000, C424S465000, C424S470000
Reexamination Certificate
active
06558699
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to high drug load formulations, processes for preparing these formulations, and methods of using high drug load formulations in the treatment of certain disease states in mammals, in particular man. Specifically, the present invention relates to the use of anhydrous (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid in the preparation of high drug load immediate and modified release tablet formulations, wet or dry granulation processes for preparing high drug load granules, oral dosage forms containing these high drug load granules, and methods of using high drug load formulations of (E)-&agr;-[2-n-butyl-1-[(4carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid to block angiotensin II (AII) receptors and to treat hypertension, congestive heart failure and renal failure.
BACKGROUND OF THE INVENTION
The compound, (E)-&agr;-[2-n-butyl-1-[(4carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid, is known by the name “eprosartan” and is the subject of U.S. Pat. No. 5,185,351 (the '351 patent), issued Feb. 9, 1993. This patent discloses a process for making the anhydrous form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid and its methane sulfonate salt. Additionally, the '351 patent discloses conventional techniques for formulating (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)-methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid. This compound is claimed to have utility in blocking angiotensin II receptors and to be useful in the treatment of hypertension, congestive heart failure and renal failure.
International Application Number PCT/US97/04877, filed Mar. 26, 1997. relates to a novel dihydrated form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate, in particular, in pharmaceutical compositions for the treatment of diseases in which blockade of angiotensin II receptors is indicated, for example, in the treatment of hypertension, congestive heart failure and renal failure. This form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophene-propionic acid monomethanesulfonate is produced during the wet granulation of the anhydrous form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)-methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate.
Surprisingly, it has been found that anhydrous (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid does not form a hydrate during wet granulation. This discovery has allowed for the preparation of reduced size, high drug load tablets. This is particularly important when formulating eprosartan for commercial use.
SUMMARY OF THE INVENTION
The present invention provides high drug load formulations of anhydrous (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid and oral solid dosage forms of this compound for the treatment of diseases in which blockade of angiotensin II receptors is indicated, for example, in the treatment of hypertension, congestive heart failure and renal failure. These high drug load formulations are in immediate or modified release oral solid dosage forms.
The present invention also provides processes for preparing high drug load tablet formulations of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]-methylene-2-thiophenepropionic acid by dry or wet granulation of the anhydrous form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid in the presence of pharmaceutically acceptable excipients.
REFERENCES:
patent: 4444769 (1984-04-01), Blume et al.
patent: 4610870 (1986-09-01), Jain et al.
patent: 5185351 (1993-02-01), Finkelstein et al.
patent: 5656650 (1997-08-01), Weinstock
patent: 5684029 (1997-11-01), Narr et al.
patent: WO-97/36874 (1997-10-01), None
patent: WO-99/00383 (1999-01-01), None
Bennett Rachel M.
Kinzig Charles M.
Madden Laura K.
McCarthy Mary E.
Page Thurman K.
LandOfFree
High drug load immediate and modified release oral dosage... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High drug load immediate and modified release oral dosage..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High drug load immediate and modified release oral dosage... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3071287